| Literature DB >> 31835729 |
Andreea Ciudin1,2,3, Angel Michael Ortiz1,3, Enzamaria Fidilio1,3, Diana Romero1, Marta Sánchez3, Marta Comas3, Oscar Gonzalez4, Ramon Vilallonga4, Olga Simó-Servat1,2,3, Cristina Hernández1,2,3, Rafael Simó1,2,3.
Abstract
BACKGROUND: There is clear association between type 2 diabetes (T2D) and cognitive decline. Retinal microperimetry is a useful tool for detecting cognitive impairment in T2D. Morbid obesity (MO) has been associated with cognitive impairment. Insulin resistance (IR) seems a major determinant, but the data are unclear. The aim of this study was to evaluate the cognitive impairment in MO as well as the utility of retinal microperimetry in identifying these alterations.Entities:
Keywords: cognitive impairment; insulin resistance; morbid obesity; retinal microperimetry
Year: 2019 PMID: 31835729 PMCID: PMC6947364 DOI: 10.3390/jcm8122181
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
The baseline characteristics of the subjects included in the study.
| Characteristics | Obese Patients | Controls |
|
|---|---|---|---|
|
| 50 | 30 | NA |
| Gender (females %) | 71.12 | 70.45 | n.s. |
| Age (years) | 45.88 ± 10.23 | 41.17 ± 12.33 | n.s. |
| BMI (kg/m2) | 44.54 ± 5.53 | 22.99 ± 3.51 | <0.001 |
| HOMA-IR | 6.43 ± 2.64 | 1.34 ± 0.68 | <0.001 |
| HbA1c (%Hb DCCT) | 5.96 ± 1.15 | 5.24 ± 0.27 | 0.001 |
| T2D duration (month) | 24 ± 9.1 | NA | NA |
| MoCA score | 24.94 ± 2.74 | 28.95 ± 1.05 | <0.001 |
| MMSE | 28.24 ± 1.14 | 29 ± 0.62 | n.s. |
MoCA but not MMSE identify cognitive impairment in subjects with morbid obesity.
The scores of the different domains evaluated by the MoCA test.
| MoCA Domains | Obese Patients | Controls |
|
|---|---|---|---|
| Visuo Spatial Executive Function | 4.0 ± 0.791 | 4.93 ± 0.26 | 0.001 |
| Naming | 2.94 ± 0.243 | 3.00 ± 0.00 | n.s. |
| Attention | 4.41 ± 1.73 | 5.67 ± 0.62 | 0.01 |
| Language | 2.71 ± 0.588 | 2.91 ± 0.32 | n.s. |
| Abstraction | 1.71 ± 0.772 | 1.96 ± 1.92 | n.s. |
| Delayed Recall | 3.14 ± 1.581 | 4.11 ± 1.31 | 0.015 |
| Orientation | 6.00 ± 0.00 | 6.00 ± 0.00 | n.s. |
| Total | 24.94 ± 2.74 | 28.95 ± 1.05 | <0.001 |
Gaze fixation assessment but not retinal sensitivity is impaired in subjects with morbid obesity and is related to MoCA (Montreal Cognition Assessment Test).
Microperimetry parameters between obese patients and control.
| Microperimetry Parameters | Obese Patients | Controls |
|
|---|---|---|---|
|
| 50 | 30 | NA |
| Sensitivity (dB) | 27.6 ± 3.81 | 29.28 ± 1.39 | n.s. |
| Fixation P1 (%) | 78.48 ± 26.16 | 97.18 ± 3.2 | 0.001 |
| Fixation P2 (%) | 90.31 ± 17.84 | 98.40 ± 4.39 | 0.001 |
| BCEA63 | 1.50 ± 1.32 | 0.40 ± 0.34 | 0.001 |
| BCEA95 | 8.33 ± 4.66 | 3.01 ± 2.01 | 0.021 |
| Reliability index | 93.52 ± 11.75 | 95.45 ± 15.07 | n.s. |
Figure 1Correlation between BCEA95 and MoCA. BCEA95: 95% bivariate contour ellipse area. MoCA: Montreal Cognitive Assessment test.
Figure 2AUROC BECA95 and cognition (MoCA). BCEA95: 95% bivariate contour ellipse area. MoCA: Montreal Cognitive Assessment test.
Comparison between MO patients with T2D and without T2D.
| Characteristics | Obese Patients with T2D | Obese Patients Without T2D |
|
|---|---|---|---|
|
| 24 | 26 | NA |
| Gender (female %) | 70.37 | 71.42 | n.s. |
| Age (years) | 47.63 ± 8.62 | 44.33 ± 11.41 | n.s. |
| BMI (kg/m2) | 44.36 ± 5.4 | 44.70 ± 5.66 | n.s. |
| HOMA-IR | 8.34 ± 2.08 | 4.71 ± 2.047 | 0.001 |
| HbA1c (%Hb DCCT) | 6.62 ± 1.3 | 5.33 ± 0.28 | 0.001 |
| T2D duration (month) | 24 ± 9.1 | NA | NA |
| MoCA score | 25.5 ± 2.61 | 24.44 ± 2.92 | n.s. |
| MMSE | 28.1 ± 1.53 | 28.09 ± 1.78 | n.s. |
| Retinal sensitivity (dB) | 27.76 ± 2.45 | 27.59 ± 4.58 | n.s. |
| Fixation P1 (%) | 82.48 ± 23.59 | 78.19 ± 27.6 | n.s |
| Fixation P2 (%) | 92.00 ± 17.21 | 89.54 ± 18.04 | n.s. |
| BCEA63 | 1.47 ± 1.44 | 1.51 ± 1.25 | n.s. |
| BCEA95 | 8.14 ± 4.5 | 8.46 ± 4.85 | n.s. |
| Reliability index | 91.52 ± 14.75 | 92.65 ± 12.96 | n.s. |
| Education level | 7.08 ± 0.33 | 7.16 ± 0.28 | n.s. |
HOMA-IR is a predictor of cognitive impairment in a multiple regression analysis model.
| Coefficients(a) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
| ||||
| 1 | (Constant) | 25.200 | 3.734 | 6.749 | 0.000 | 17.684 | 32.715 | |||
| Gender | −0.503 | 0.776 | −0.084 | −0.648 | 0.520 | −2.065 | 1.060 | 0.869 | 1.151 | |
| Age | −0.063 | 0.034 | −0.242 | −1.823 | 0.075 | −0.132 | 0.007 | 0.831 | 1.203 | |
| Type 2 Diabetes | −0.169 | 0.286 | −0.076 | 0.589 | 0.559 | −0.745 | 0.408 | 0.888 | 1.127 | |
| HbA1c levels | 0.233 | 0.375 | 0.081 | 0.620 | 0.538 | −0.523 | 0.989 | 0.869 | 1.151 | |
| BMI | 0.078 | 0.050 | 0.209 | 1.574 | 0.122 | −0.022 | 0.179 | 0.836 | 1.196 | |
| HOMA-IR | −0.149 | 0.053 | −0.375 | −2.836 | 0.007 | −0.255 | −0.043 | 0.842 | 1.188 | |
a. Dependent Variable: MoCA score.
Figure 3Correlation between MoCA score and HOMA-IR. MoCA: Montreal Congnitive Assessment test. HOMA-IR: Homeostatic model assessment for insulin-resistance.
Figure 4Correlation between BCEA95 and HOMA-IR. BCEA95: 95% bivariate contour ellipse area. HOMA-IR: Homeostatic model assessment for insulin-resistance.